GlaxoSmithKline's Witty Plays Down Impact Of US Health Care Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK's sales rose by 16 percent in the first quarter, driven by vaccines, respiratory, dermatology and consumer products, particularly in emerging markets.